Södertälje Municipality

2,000 Employees Across 15+ Industries Reveal Bad Managers and Burnout Are Causing Them To Quit, Joining The Great Resignation; Hybrid Work Challenges and Poor Communication Are also Key Factors

Retrieved on: 
Wednesday, August 4, 2021
Other Professional Services, Software, Human Resources, Internet, Consulting, Small Business, Professional Services, Technology, Companies, AstraZeneca, Medical research, Södertälje Municipality, LVMH, Oxford–AstraZeneca COVID-19 vaccine

To uncover why people are leaving their jobs, The Predictive Index surveyed nearly 2,000 employees across 15+ industries in a new report published today, The 2021 People Management Report .

Key Points: 
  • To uncover why people are leaving their jobs, The Predictive Index surveyed nearly 2,000 employees across 15+ industries in a new report published today, The 2021 People Management Report .
  • For organizations to avoid The Great Resignation, they need to listen to their people and mount a Great Retention instead.
  • When compared to results from the previous report, communication shot up four spots on the list, from number five to number one.
  • More than 8,000 clients use PIincluding AstraZeneca, Blue Cross Blue Shield, TD Bank, LVMH, and Omni Hotelsacross 142+ countries.

Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021
Stars, Companies, Life sciences, AstraZeneca, Medical research, Södertälje Municipality, Oxford–AstraZeneca COVID-19 vaccine, Wedbush Securities, Albireo, NASDAQ

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at3:30 p.m.

Key Points: 
  • BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at3:30 p.m.
  • The live webcast of the presentation will be accessible from the Media & Investors page of Albireos website, ir.albireopharma.com .
  • Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.
  • The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Albireo to Report Second Quarter 2021 Financial Results on August 5

Retrieved on: 
Thursday, July 29, 2021
Regions of the United States, Stars, Geography of the United States, Greater Boston, AstraZeneca, Medical research, Södertälje Municipality, Albireo, Oxford–AstraZeneca COVID-19 vaccine, Boston, Massachusetts

ET onAugust 5, 2021, to provide a business update and review the companys financial results for the second quarter ended June 30, 2021.

Key Points: 
  • ET onAugust 5, 2021, to provide a business update and review the companys financial results for the second quarter ended June 30, 2021.
  • To access the live conference call by phone, please dial 877-407-0792(domestic) or 201-689-8263 (international), and provide the access code 13720893.
  • Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.
  • The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Monday, July 26, 2021
Biotechnology, Health, Oncology, Companies, Life sciences, Industry economics), AstraZeneca, Medical research, Södertälje Municipality, Arcus

The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.

Key Points: 
  • The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
  • An additional registrational Phase 3 study is being planned in collaboration with AstraZeneca in earlier disease with curative intent.
  • For more information about Arcus Biosciences, please visit www.arcusbio.com .

HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca

Retrieved on: 
Tuesday, July 13, 2021
Life sciences, Health sciences, Companies, AstraZeneca, Medical research, Södertälje Municipality, Cancer, AZN, Oxford–AstraZeneca COVID-19 vaccine

Under the terms of the license and collaboration agreement between HUTCHMED and AstraZeneca (AstraZeneca) (LSE/STO/Nasdaq: AZN), a US$25 million non-creditable and non-refundable milestone payment is triggered by the first commercial sales of ORPATHYS in China.

Key Points: 
  • Under the terms of the license and collaboration agreement between HUTCHMED and AstraZeneca (AstraZeneca) (LSE/STO/Nasdaq: AZN), a US$25 million non-creditable and non-refundable milestone payment is triggered by the first commercial sales of ORPATHYS in China.
  • It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers, as a single treatment and in combination with other medicines.
  • The safety and tolerability profile of ORPATHYS was consistent with previous trials, and no new safety signals were identified.
  • Patients whose tumors harbor MET amplification were treated with ORPATHYS monotherapy, reporting an ORR of 50% (10/20, 95% CI: 28.0, 71.9).

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Monday, July 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Companies, Life sciences, Industry economics), AstraZeneca, Medical research, Södertälje Municipality, Arcus

The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.

Key Points: 
  • The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
  • An additional registrational Phase 3 study is being planned in collaboration with AstraZeneca in earlier disease with curative intent.
  • For more information about Arcus Biosciences, please visit www.arcusbio.com .

F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors

Retrieved on: 
Thursday, July 8, 2021
Medical specialties, Medicine, Health care, Immune system, AstraZeneca, Medical research, Södertälje Municipality, Immunology, Oxford–AstraZeneca COVID-19 vaccine, Autoimmune disease, Autoimmunity, Stimulator of interferon genes

Under the terms of the agreement, AstraZeneca is granted exclusive access to F-stars novel preclinical STING inhibitors.

Key Points: 
  • Under the terms of the agreement, AstraZeneca is granted exclusive access to F-stars novel preclinical STING inhibitors.
  • Neil Brewis, Chief Scientific Officer of F-star, said, We are excited to announce this agreement with AstraZeneca to develop these promising drug candidates.
  • STING inhibitors offer enormous potential for new treatments, as STING is known to play a role in activating the innate immune system across a range of inflammatory and autoimmune diseases.
  • We are confident that AstraZeneca can maximize the value of these discovery stage compounds to benefit patients.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Thursday, June 24, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Companies, Life sciences, Industry economics), AstraZeneca, Medical research, Södertälje Municipality, Arcus

The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.

Key Points: 
  • The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
  • An additional registrational Phase 3 study is being planned in collaboration with AstraZeneca in earlier disease with curative intent.
  • For more information about Arcus Biosciences, please visit www.arcusbio.com or follow us on Twitter .

Scania scores its fifth consecutive 'Green Truck' victory

Retrieved on: 
Thursday, June 10, 2021
TRATON, Engines, Scania AB, Södertälje Municipality, MAN SE

SDERTLJE, Sweden, June 10, 2021 /PRNewswire/ -- For the fifth year running, Scania has won Germany's coveted 'Green Truck' title.

Key Points: 
  • SDERTLJE, Sweden, June 10, 2021 /PRNewswire/ -- For the fifth year running, Scania has won Germany's coveted 'Green Truck' title.
  • "Winning this test five years in a row is a feat that should not be possible, yet we've still done it.
  • "Although electrification is on its way, we need the most efficient combustion engines to reach the Paris Agreement targets, something which Scania is committed to."
  • rjan slund, Head of Product Affairs and Press Testing, Scania Trucks
    Phone: + 46 70 289 83 78, E-mail: [email protected]

Howard University College of Pharmacy, AstraZeneca Tackle Cancer With New Post-Graduate Fellowships

Retrieved on: 
Friday, June 4, 2021
Companies, Life sciences, AstraZeneca, Medical research, Södertälje Municipality, Howard University, Pharmacy school

We are thrilled to partner with AstraZeneca to create new opportunities to further scientific, regulatory and industry efforts to fight cancer, said Howard University Provost and Chief Academic Officer Anthony Wutoh, Ph.D.

Key Points: 
  • We are thrilled to partner with AstraZeneca to create new opportunities to further scientific, regulatory and industry efforts to fight cancer, said Howard University Provost and Chief Academic Officer Anthony Wutoh, Ph.D.
  • Both two-year AstraZeneca fellowships are open to Howard University graduates and comes with adjunct faculty appointments.
  • Dr. Ettienne has worked diligently to make this come to fruition, said Howard University College of Pharmacy Dean Toyin Tofade.
  • Founded in 1867, Howard University is a private, research university that is comprised of 13 schools and colleges.